TP53 and neoplasm: Through the National Cancer Institute’s 60 human tumor cell line anticancer drug screening, the zinc metallochaperone-1 (ZMC1) was identified, which selectively targets p53(R175H), inducing apoptosis and tumor regression in p53(R175H)-expressing cells while sparing wtp53 cells [47].